Edition:
United States

Merck & Co Inc (MRK)

MRK on New York Consolidated

65.13USD
22 Sep 2017
Change (% chg)

$-0.47 (-0.72%)
Prev Close
$65.60
Open
$65.63
Day's High
$65.70
Day's Low
$65.07
Volume
7,465,879
Avg. Vol
8,203,577
52-wk High
$66.80
52-wk Low
$58.29

Chart for

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.82
Market Cap(Mil.): $177,632.59
Shares Outstanding(Mil.): 2,727.35
Dividend: 0.47
Yield (%): 2.89

Financials

  Industry Sector
P/E (TTM): -- 31.67 16.08
EPS (TTM): -- -- --
ROI: -- 15.12 14.60
ROE: -- 16.35 14.03

BRIEF-Merck says FDA approves Keytruda(pembrolizumab) for previously treated patients

* Fda approves Merck’s keytruda® (pembrolizumab) for previously treated patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer whose tumors express pd-l1 (cps greater than or equal to 1)

Sep 22 2017

BRIEF-Merck says Isentress HD now available in Canada

* Now available in Canada: Isentress HD (raltegravir), a new once-daily option, in combination with other antiretroviral agents, for the treatment of HIV-1 infection in appropriate patients

Sep 12 2017

BRIEF-Merck announces findings from phase 3 study of KEYTRUDA

* Merck announces findings from phase 3 study of KEYTRUDA (pembrolizumab), compared to standard of care, in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma

Sep 11 2017

Bristol-Myers says FDA places partial hold on Opdivo myeloma trials

The U.S. Food and Drug Administration has placed a partial hold on three clinical trials testing Bristol-Myers Squibb's immunotherapy Opdivo in combination with other medicines for multiple myeloma due to risks seen in similar studies involving a rival drug, the company said on Wednesday.

Sep 06 2017

Bristol-Myers says FDA places partial hold on Opdivo myeloma trials

Sept 6 The U.S. Food and Drug Administration has placed a partial hold on three clinical trials testing Bristol-Myers Squibb's immunotherapy Opdivo in combination with other medicines for multiple myeloma due to risks seen in similar studies involving a rival drug, the company said on Wednesday.

Sep 06 2017

Merck & Co snaps up three year-old German biotech firm for up to $550 million

FRANKFURT U.S. pharma group Merck & Co has acquired 3-1/2 year old German biotech start-up Rigontec for up to 464 million euros ($554 million), adding a new approach to its development of drugs that spur the immune system to attack tumors.

Sep 06 2017

Merck & Co snaps up 3 yr-old German biotech firm for up to $550 mln

FRANKFURT, Sept 6 U.S. pharma group Merck & Co has acquired 3-1/2 year old German biotech start-up Rigontec for up to 464 million euros ($554 million), adding a new approach to its development of drugs that spur the immune system to attack tumours.

Sep 06 2017

BRIEF-European Commission approves Merck’S KEYTRUDA (pembrolizumab)

* European Commission approves Merck’s KEYTRUDA (pembrolizumab) for the treatment of certain patients with locally advanced or metastatic urothelial carcinoma, a type of bladder cancer

Sep 05 2017

BRIEF-Merck announces results of REVEAL outcomes study of Anacetrapib

* Merck announces results of REVEAL outcomes study of Anacetrapib, investigational medicine for cardiovascular disease

Aug 29 2017

Merck cholesterol drug cuts heart risk by 9 pct in study

Aug 29 A large study of Merck & Co Inc's experimental cholesterol drug anacetrapib found that it cut the risk of heart attack and death by a modest 9 percent, which could be due to its affect on bad LDL cholesterol, researchers said on Tuesday.

Aug 29 2017

Competitors

Earnings vs. Estimates